Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza
Seizaburo Kashiwagi,Akira Watanabe,Hideyuki Ikematsu,Mitsutoshi Uemori,Shinichiro Awamura,Seizaburo Kashiwagi,Akira Watanabe,Hideyuki Ikematsu,Katsuyasu Ishida,Shinichiro Awamura,Satoshi Nishioka,Koji Isobe,Tokuhito Sumitani,Mitsutoshi Uemori,Toshiko Yamaguchi,Yutaka Igarashi,Hideki Sato,Kouta Saito,Tomoyuki Shibuya,Shinya Enomoto,Eiki Oshika,Yasuko Murakawa,Haruo Kuroki,Koji Maehara,Yuko Miyazono,Yoshihiro Umezawa,Ryuta Ono,Kenji Saito,Jiro Takei,Mikiko Takano,Hideki Amemiya,Kazuo Arakawa,Shigenori Matsubara,Kazumasa Sugimoto,Hiroshi Kikumori,Toshihiko Sunami,Ryota Yoshimura,Toshikazu Takahashi,Yutaka Nakamura,Keiichi Tsuboi,Hidehisa Shinohara,Shigeru Onari,Michiko Tanabe,Hiroshi Taniguchi,Mikio Kihara,Tatsuo Yoshimitsu,Takato Yokoyama,Yoshio Takasaki,Yuji Yamashita,Hiroshi Harada,Katsumaro Aida,Shizuo Shindo,Kunihisa Shimomura,Yumi Kiyomatsu,Toru Umezu,Motohisa Ikeda,Minako Iwaya,Masaki Higashikawa,Takeshi Inamitsu,Yasuyuki Tokunaga,Satoru Okazaki,Yoichi Tokunaga,Tetsunari Maeda,Hirofumi Tahara
DOI: https://doi.org/10.1093/cid/ciw255
IF: 20.999
2016-04-26
Clinical Infectious Diseases
Abstract:BACKGROUND: A single administration of laninamivir octanoate, a long-acting neuraminidase inhibitor, has been proven to be effective in the treatment of influenza but not for post-exposure prophylaxis.METHODS: We conducted a double-blind, multicenter, randomized, placebo-controlled study to determine if a single administration of laninamivir octanoate 40 mg was superior to placebo for post-exposure prophylaxis. Eligible participants who had cohabited with an influenza patient within 48 hours of symptom onset were randomly assigned (1:1:1) to 1 of 3 groups: 40 mg of laninamivir octanoate single administration (LO-40SD), 20 mg of laninamivir octanoate once daily for 2 days (LO-20TD), or placebo. The primary efficacy endpoint was the proportion of participants who developed clinical influenza (defined as influenza virus positive, an axillary temperature >37.5°C, and at least 2 symptoms) over a 10-day period.RESULTS: A total of 803 participants were enrolled, with 801 included in the primary analysis. The proportions of participants with clinical influenza were 4.5% (12/267), 4.5% (13/269), and 12.1% (32/265) in the LO-40SD, LO-20TD, and placebo groups, respectively. A single administration of laninamivir octanoate 40 mg significantly reduced the development of influenza compared with placebo (P = .001). The relative risk reductions compared with the placebo group were 62.8% and 63.1% for the LO-40SD and LO-20TD groups, respectively. The incidence of adverse events in the LO-40SD group was similar to that of the LO-20TD and placebo groups.CONCLUSIONS: A single administration of laninamivir octanoate was effective and well tolerated as post-exposure prophylaxis to prevent the development of influenza.CLINICAL TRIALS REGISTRATION: JapicCTI-142679.
immunology,infectious diseases,microbiology